Back to top Open menu arrow
Download Reprints
Sections
METHODS RESULTS DISCUSSION Conclusion Clinical points
The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry
Access icon

Original Research Early Career Psychiatrists August 10, 2021

Inflammation and Cognitive Functioning in Depressed Older Adults Treated With Electroconvulsive Therapy: A Prospective Cohort Study

Angela Carlier, MD; Didi Rhebergen, MD, PhD; Robert Veerhuis, PhD; Sigfried Schouws, PhD; Mardien L. Oudega, MD, PhD; Piet Eikelenboom, MD, PhD; Filip Bouckaert, MD, PhD; Pascal Sienaert, MD, PhD; Jasmien Obbels, MSc; Max L. Stek, MD, PhD; Eric van Exel, MD, PhD; Annemiek Dols, MD, PhD

J Clin Psychiatry 2021;82(5):20m13631

ABSTRACT

Objective: Despite the effectiveness of electroconvulsive therapy (ECT), patients and practitioners are often reluctant to start it due to the risk of transient cognitive side effects, particularly in older patients. Inflammatory processes may be associated with the occurrence of these effects. This study assessed whether inflammatory markers prior to ECT are associated with cognitive functioning in depressed patients treated with ECT.

Methods: Between 2011 and 2013, 97 older patients (mean [SD] age = 73.1 [8.1] years) with severe unipolar depression (according to DSM-IV) referred for ECT were included. Mini-Mental State Examination (MMSE) scores were used to determine cognitive functioning prior to, weekly during, and in the first week after a course of ECT. Serum levels of C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-10 (IL-10), and tumor necrosis factor-α (TNF-α) were assessed prior to ECT.

Results: In fully adjusted models, there was an association between TNF-α and cognitive functioning (β = −1.05; 95% CI, −2.04 to −0.06; f2 = 0.06). An association was also found between baseline levels of IL-10 and TNF-α and lower MMSE scores during ECT (IL-10: β = −2.08; 95% CI, −3.22 to −0.95; TNF-α: β = −0.65; 95% CI, −1.07 to −0.22). In addition, an association was found between baseline CRP and lower MMSE scores directly after a course of ECT (β = −0.51; 95% CI, −0.93 to −0.09; f2 = 0.10). Associations with IL-6 did not reach significance.

Conclusions: This study suggests that inflammatory processes are associated with lower cognitive functioning prior to ECT and predispose for further cognitive dysfunction during and after a course of ECT.

Trial registration: ClinicalTrials.gov identifier: NCT02667353

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

  1. Geduldig ET, Kellner CH. Electroconvulsive therapy in the elderly: new findings in geriatric depression. Curr Psychiatry Rep. 2016;18(4):40. PubMed CrossRef
  2. Rhee TG, Olfson M, Sint K, et al. Characterization of the quality of electroconvulsive therapy among older medicare beneficiaries. J Clin Psychiatry. 2020;81(4):19m13186. PubMed CrossRef
  3. Chakrabarti S, Grover S, Rajagopal R. Electroconvulsive therapy: a review of knowledge, experience and attitudes of patients concerning the treatment. World J Biol Psychiatry. 2010;11(3):525–537. PubMed CrossRef
  4. Obbels J, Verwijk E, Bouckaert F, et al. ECT-related anxiety: a systematic review. J ECT. 2017;33(4):229–236. PubMed CrossRef
  5. Kikuchi A, Yasui-Furukori N, Fujii A, et al. Identification of predictors of post-ictal delirium after electroconvulsive therapy. Psychiatry Clin Neurosci. 2009;63(2):180–185. PubMed CrossRef
  6. Reti IM, Krishnan A, Podlisky A, et al. Predictors of electroconvulsive therapy postictal delirium. Psychosomatics. 2014;55(3):272–279. PubMed CrossRef
  7. Fraser LM, O’Carroll RE, Ebmeier KP. The effect of electroconvulsive therapy on autobiographical memory: a systematic review. J ECT. 2008;24(1):10–17. PubMed CrossRef
  8. Semkovska M, McLoughlin DM. Objective cognitive performance associated with electroconvulsive therapy for depression: a systematic review and meta-analysis. Biol Psychiatry. 2010;68(6):568–577. PubMed CrossRef
  9. Andrade C, Arumugham SS, Thirthalli J. Adverse effects of electroconvulsive therapy. Psychiatr Clin North Am. 2016;39(3):513–530. PubMed CrossRef
  10. Kumar S, Mulsant BH, Liu AY, et al. Systematic review of cognitive effects of electroconvulsive therapy in late-life depression. Am J Geriatr Psychiatry. 2016;24(7):547–565. PubMed CrossRef
  11. Obbels J, Vansteelandt K, Verwijk E, et al. MMSE changes during and after ECT in late-life depression: a prospective study. Am J Geriatr Psychiatry. 2019;27(9):934–944. PubMed CrossRef
  12. Oudega ML, van Exel E, Wattjes MP, et al. White matter hyperintensities and cognitive impairment during electroconvulsive therapy in severely depressed elderly patients. Am J Geriatr Psychiatry. 2014;22(2):157–166. PubMed CrossRef
  13. Hausner L, Damian M, Sartorius A, et al. Efficacy and cognitive side effects of electroconvulsive therapy (ECT) in depressed elderly inpatients with coexisting mild cognitive impairment or dementia. J Clin Psychiatry. 2011;72(1):91–97. PubMed CrossRef
  14. Obbels J, Verwijk E, Vansteelandt K, et al. Long-term neurocognitive functioning after electroconvulsive therapy in patients with late-life depression. Acta Psychiatr Scand. 2018;138(3):223–231. PubMed CrossRef
  15. Verwijk E, Comijs HC, Kok RM, et al. Short- and long-term neurocognitive functioning after electroconvulsive therapy in depressed elderly: a prospective naturalistic study. Int Psychogeriatr. 2014;26(2):315–324. PubMed CrossRef
  16. Kumar DR, Han HK, Tiller J, et al. A brief measure for assessing patient perceptions of cognitive side effects after electroconvulsive therapy: the subjective assessment of memory impairment. J ECT. 2016;32(4):256–261. PubMed CrossRef
  17. Mignone S, Zufferey C, De Anstiss H. Family experiences of caring for relatives who have received electroconvulsive therapy (ECT). Aust Soc Work. 2018;71(1):86–97. CrossRef
  18. Sethi S, Williams RA. The family caregiving experience of outpatient ECT. J Am Psychiatr Nurses Assoc. 2003;9(6):187–194. CrossRef
  19. Choi J, Wang Y, Feng T, et al. Cognitive training to improve memory in individuals undergoing electroconvulsive therapy: negative findings. J Psychiatr Res. 2017;92:8–14. PubMed CrossRef
  20. Mohagheghi A, Arfaie A, Amiri S, et al. Preventive effect of liothyronine on electroconvulsive therapy-induced memory deficit in patients with major depressive disorder: a double-blind controlled clinical trial. BioMed Res Int. 2015;2015:503918. PubMed CrossRef
  21. Kellner CH, Adams DA, Benferhat A. Further improving the cognitive effect profile of electroconvulsive therapy (ECT): the case for studying carbamylated erythropoietin. Med Hypotheses. 2015;84(3):258–261. PubMed CrossRef
  22. Schmidt LS, Petersen JZ, Vinberg M, et al. Erythropoietin as an add-on treatment for cognitive side effects of electroconvulsive therapy: a study protocol for a randomized controlled trial. Trials. 2018;19(1):234. PubMed CrossRef
  23. Henstra MJ, Jansma EP, van der Velde N, et al. Acetylcholinesterase inhibitors for electroconvulsive therapy-induced cognitive side effects: a systematic review. Int J Geriatr Psychiatry. 2017;32(5):522–531. PubMed CrossRef
  24. van Schaik AM, Rhebergen D, Henstra MJ, et al. Cognitive impairment and electroconvulsive therapy in geriatric depression, what could be the role of rivastigmine? a case series. Clin Pract. 2015;5(3):780. PubMed CrossRef
  25. Martin DM, Gálvez V, Loo CK. Predicting retrograde autobiographical memory changes following electroconvulsive therapy: Relationships between individual, treatment, and early clinical factors. Int J Neuropsychopharmacol. 2015;18(12):1–8. PubMed CrossRef
  26. van Oostrom I, van Eijndhoven P, Butterbrod E, et al. Decreased cognitive functioning after electroconvulsive therapy is related to increased hippocampal volume: exploring the role of brain plasticity. J ECT. 2018;34(2):117–123. PubMed CrossRef
  27. Socci C, Medda P, Toni C, et al. Electroconvulsive therapy and age: age-related clinical features and effectiveness in treatment resistant major depressive episode. J Affect Disord. 2018;227:627–632. PubMed CrossRef
  28. McCall WV, Reboussin DM, Weiner RD, et al. Titrated moderately suprathreshold vs fixed high-dose right unilateral electroconvulsive therapy: acute antidepressant and cognitive effects. Arch Gen Psychiatry. 2000;57(5):438–444. PubMed CrossRef
  29. Semkovska M, Landau S, Dunne R, et al. Bitemporal versus high-dose unilateral twice-weekly electroconvulsive therapy for depression (EFFECT-Dep): a pragmatic, randomized, non-inferiority trial. Am J Psychiatry. 2016;173(4):408–417. PubMed CrossRef
  30. Verwijk E, Comijs HC, Kok RM, et al. Neurocognitive effects after brief pulse and ultrabrief pulse unilateral electroconvulsive therapy for major depression: a review. J Affect Disord. 2012;140(3):233–243. PubMed CrossRef
  31. Pigot M, Andrade C, Loo C. Pharmacological attenuation of electroconvulsive therapy–induced cognitive deficits: theoretical background and clinical findings. J ECT. 2008;24(1):57–67. PubMed CrossRef
  32. Laroy M, Bouckaert F, Vansteelandt K, et al. Association between hippocampal volume change and change in memory following electroconvulsive therapy in late-life depression. Acta Psychiatr Scand. 2019;140(5):435–445. PubMed CrossRef
  33. Maclullich AMJ, Ferguson KJ, Miller T, et al. Unravelling the pathophysiology of delirium: a focus on the role of aberrant stress responses. J Psychosom Res. 2008;65(3):229–238. PubMed CrossRef
  34. Maldonado JR. Delirium pathophysiology: An updated hypothesis of the etiology of acute brain failure. Int J Geriatr Psychiatry. 2018;33(11):1428–1457. PubMed CrossRef
  35. Liu X, Yu Y, Zhu S. Inflammatory markers in postoperative delirium (POD) and cognitive dysfunction (POCD): a meta-analysis of observational studies. PLoS One. 2018;13(4):e0195659. PubMed CrossRef
  36. Carlier A, Berkhof JG, Rozing M, et al. Inflammation and remission in older patients with depression treated with electroconvulsive therapy; findings from the MODECT study. J Affect Disord. 2019;256:509–516. PubMed CrossRef
  37. Kruse JL, Congdon E, Olmstead R, et al. Inflammation and improvement of depression following electroconvulsive therapy in treatment-resistant depression. J Clin Psychiatry. 2018;79(2):17m11597. PubMed CrossRef
  38. Dols A, Bouckaert F, Sienaert P, et al. Early- and late-onset depression in late life: a prospective study on clinical and structural brain characteristics and response to electroconvulsive therapy. Am J Geriatr Psychiatry. 2017;25(2):178–189. PubMed CrossRef
  39. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Washington, DC: American Psychiatric Press; 1994.
  40. Amorim P, Lecrubier Y, Weiller E, et al. The Mini International Neuropsychiatric Interview. Eur Psychiatry. 1998;13(S4):198S.CrossRef
  41. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–198. PubMed CrossRef
  42. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6):448–454. PubMed CrossRef
  43. Felger JC, Lotrich FE. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience. 2013;246:199–229. PubMed CrossRef
  44. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22–34. PubMed CrossRef
  45. Enache D, Pariante CM, Mondelli V. Markers of central inflammation in major depressive disorder: a systematic review and meta-analysis of studies examining cerebrospinal fluid, positron emission tomography and post-mortem brain tissue. Brain Behav Immun. 2019;81:24–40. PubMed CrossRef
  46. Gabryšová L, Howes A, Saraiva M, et al. The regulation of IL-10 expression. Curr Top Microbiol Immunol. 2014;380:157–190. PubMed
  47. Lobo-Silva D, Carriche GM, Castro AG, et al. Balancing the immune response in the brain: IL-10 and its regulation. J Neuroinflammation. 2016;13(1):297. PubMed CrossRef
  48. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382–389. PubMed CrossRef
  49. van den Broek WW, Birkenhäger TK, de Boer D, et al. Guideline Electroconvulsive Therapy [Richtlijn Elektroconvulsietherapie]. Utrecht: de Tijdstroom; 2010.
  50. Campos MW, Serebrisky D, Castaldelli-Maia JM. Smoking and cognition. Curr Drug Abuse Rev. 2016;9(2):76–79. PubMed CrossRef
  51. Hassing LB. Light alcohol consumption does not protect cognitive function: a longitudinal prospective study. Front Aging Neurosci. 2018;10:81. PubMed CrossRef
  52. Hogenkamp PS, Benedict C, Sjögren P, et al. Late-life alcohol consumption and cognitive function in elderly men. Age (Dordr). 2014;36(1):243–249. PubMed CrossRef
  53. Osimo EF, Cardinal RN, Jones PB, et al. Prevalence and correlates of low-grade systemic inflammation in adult psychiatric inpatients: an electronic health record-based study. Psychoneuroendocrinology. 2018;91:226–234. PubMed CrossRef
  54. Qiu F, Liang C-L, Liu H, et al. Impacts of cigarette smoking on immune responsiveness: up and down or upside down? Oncotarget. 2017;8(1):268–284. PubMed CrossRef
  55. Szabo G. Alcohol’s contribution to compromised immunity. Alcohol Health Res World. 1997;21(1):30–41. PubMed
  56. Wang R, Fratiglioni L, Kalpouzos G, et al. Mixed brain lesions mediate the association between cardiovascular risk burden and cognitive decline in old age: s population-based study. Alzheimers Dement. 2017;13(3):247–256. PubMed CrossRef
  57. Cohen J. A power primer. Psychol Bull. 1992;112(1):155–159. PubMed CrossRef
  58. Perneger TV. What’s wrong with Bonferroni adjustments. BMJ. 1998;316(7139):1236–1238. PubMed CrossRef
  59. Simpson EEA, Hodkinson CF, Maylor EA, et al. Intracellular cytokine production and cognition in healthy older adults. Psychoneuroendocrinology. 2013;38(10):2196–2208. PubMed CrossRef
  60. Cezaretto A, Almeida-Pititto B, Alencar GP, et al; on the behalf of the ELSA-Brasil researchers. Utility of combined inflammatory biomarkers for the identification of cognitive dysfunction in non-diabetic participants of the ELSA-Brasil. Psychoneuroendocrinology. 2019;103:61–66. PubMed CrossRef
  61. Harrison SL, de Craen AJM, Kerse N, et al. Predicting risk of cognitive decline in very old adults using three models: the Framingham Stroke Risk Profile; the Cardiovascular Risk Factors, Aging, and Dementia Model; and oxi-inflammatory biomarkers. J Am Geriatr Soc. 2017;65(2):381–389. PubMed CrossRef
  62. Yang J, Fan C, Pan L, et al. C-reactive protein plays a marginal role in cognitive decline: a systematic review and meta-analysis. Int J Geriatr Psychiatry. 2015;30(2):156–165. PubMed CrossRef
  63. Misiak B, Beszłej JA, Kotowicz K, et al. Cytokine alterations and cognitive impairment in major depressive disorder: from putative mechanisms to novel treatment targets. Prog Neuropsychopharmacol Biol Psychiatry. 2018;80(pt C):177–188. PubMed CrossRef
  64. Walker KA, Gottesman RF, Wu A, et al. Systemic inflammation during midlife and cognitive change over 20 years: the ARIC Study. Neurology. 2019;92(11):e1256–e1267. PubMed
  65. Millett CE, Perez-Rodriguez M, Shanahan M, et al. C-reactive protein is associated with cognitive performance in a large cohort of euthymic patients with bipolar disorder [published online ahead of print November 19, 2019]. Mol Psychiatry. PubMed CrossRef
  66. Krogh J, Benros ME, Jørgensen MB, et al. The association between depressive symptoms, cognitive function, and inflammation in major depression. Brain Behav Immun. 2014;35:70–76. PubMed CrossRef
  67. Dik MG, Jonker C, Hack CE, et al. Serum inflammatory proteins and cognitive decline in older persons. Neurology. 2005;64(8):1371–1377. PubMed CrossRef
  68. Matsushima J, Kawashima T, Nabeta H, et al. Association of inflammatory biomarkers with depressive symptoms and cognitive decline in a community-dwelling healthy older sample: a 3-year follow-up study. J Affect Disord. 2015;173:9–14. PubMed CrossRef
  69. van den Biggelaar AHJJ, Gussekloo J, de Craen AJMM, et al. Inflammation and interleukin-1 signaling network contribute to depressive symptoms but not cognitive decline in old age. Exp Gerontol. 2007;42(7):693–701. PubMed CrossRef
  70. Kargar M, Yousefi A, Mojtahedzadeh M, et al. Effects of celecoxib on inflammatory markers in bipolar patients undergoing electroconvulsive therapy: a placebo-controlled, double-blind, randomised study. Swiss Med Wkly. 2014;144:w13880. PubMed CrossRef
  71. Pendlebury ST, Cuthbertson FC, Welch SJV, et al. Underestimation of cognitive impairment by Mini-Mental State Examination versus the Montreal Cognitive Assessment in patients with transient ischemic attack and stroke: a population-based study. Stroke. 2010;41(6):1290–1293. PubMed CrossRef
  72. Houx PJ, Shepherd J, Blauw GJ, et al. Testing cognitive function in elderly populations: the PROSPER study.,PROspective Study of Pravastatin in the Elderly at Risk. J Neurol Neurosurg Psychiatry. 2002;73(4):385–389. PubMed CrossRef
  73. Moirand R, Galvao F, Lecompte M, et al. Usefulness of the Montreal Cognitive Assessment (MoCA) to monitor cognitive impairments in depressed patients receiving electroconvulsive therapy. Psychiatry Res. 2018;259:476–481. PubMed CrossRef
  74. Tielkes CEM, Comijs HC, Verwijk E, et al. The effects of ECT on cognitive functioning in the elderly: a review. Int J Geriatr Psychiatry. 2008;23(8):789–795. PubMed CrossRef
  75. Tierney MC, Szalai JP, Snow WG, et al. Domain specificity of the subtests of the Mini-Mental State Examination. Arch Neurol. 1997;54(6):713–716. PubMed CrossRef
  76. Gałecki P, Talarowska M, Anderson G, et al. Mechanisms underlying neurocognitive dysfunctions in recurrent major depression. Med Sci Monit. 2015;21:1535–1547. PubMed CrossRef
  77. Spaans HP, Verwijk E, Comijs HC, et al. Efficacy and cognitive side effects after brief pulse and ultrabrief pulse right unilateral electroconvulsive therapy for major depression: a randomized, double-blind, controlled study. J Clin Psychiatry. 2013;74(11):e1029–e1036. PubMed CrossRef
Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

Save Save

Share Share

Cite Cite

Vol 85 • 2024 • Number 3

Read the Current Issue

Editorial

Focus on Women’s Mental Health: Twenty Years and Counting

Original Research

Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants

Commentary

Can Our Collective Experiences As Clinicians Improve Mental Health Care?

Original Research

Prescription Opioid Use Disorder in US Adults Reporting Prescription Opioid Use

Original Research

Symptomatic Disorders Comorbid with Borderline Personality Disorder Over Time

Original Research

Aripiprazole Lauroxil Initiation Regimens
View current Issue

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe